Background -Hepatitis C virus (HCV) infection has recently been incriminated as an aetiological agent in idiopathic pulmonary fibrosis. This study was performed to determine the cellularity and lymphocyte phenotypes ofbronchoalveolar lavage (BAL) fluid in patients with chronic hepatitis C. Methods -BAL fluid and lavage lymphocyte subsets from 13 patients (10 men) with active chronic hepatitis C, diagnosed by sustained elevated serum glutamic pyruvic transaminase and typical histological findings in the liver, were analysed. Lavage findings in these patients were compared with those from 13 healthy volunteers (eight men) as controls. To elucidate whether HCV infection is related to the pathogenesis ofIPF, we investigated the cellularity and lymphocyte phenotypes of bronchoalveolar lavage (BAL) fluid, and performed pulmonary function tests in patients with chronic hepatitis C.
Idiopathic pulmonary fibrosis (IPF) is characterised by inflammation and fibrosis of the pulmonary interstitium and peripheral air spaces.' The aetiology of IPF remains unknown. One interesting and important possible cause is viral infection.2 Hepatitis C virus (HCV), the RNA virus discovered in 1989,3 is the cause of non-A, non-B hepatitis. One of the pathological manifestations of HCV is fibrotic changes in the liver. 4 Ueda et al5 have reported an unusually high prevalence of serum antibodies to HCV in Japanese patients with IPF, and speculated that HCV may play an important part in the pathogenesis of IPF. However, Irving and coworkers6 have suggested that HCV infection is no more prevalent in patients with IPF than in the general population in the UK.
To elucidate whether HCV infection is related to the pathogenesis ofIPF, we investigated the cellularity and lymphocyte phenotypes of bronchoalveolar lavage (BAL) fluid, and performed pulmonary function tests in patients with chronic hepatitis C.
Methods

SUBJECTS
Thirteen patients (10 men) of median age 57 years (range 31-64) with chronic hepatitis C proven by the typical histological findings observed within the previous six months and the presence of sustained elevated serum levels of glutamic pyruvic transaminase (GPT) for at least six months were studied. All patients were positive for antibody to HCV in serum and negative for hepatitis B surface antigen. They were treated with interferon after this study. The following patients were excluded from the study: those who had received a course of antiviral or immunosuppresive therapy which may lead to alveolitis within six months; those who had a positive titre for autoantibodies to collagen diseases; those who exhibited leucopenia (<3000/ml) and thrombopenia (<80 000/ml). None A fibreoptic bronchoscope (Olympus BF 1T, ED 6 mm, Olympus Co, Tokyo, Japan) was wedged in the middle lobe segmental bronchus. Three 50 ml aliquots of sterile normal saline warmed to 37°C were instilled into the lung and each aliquot was then removed by gentle suction. The BAL fluid was filtered through gauze. One small aliquot was used for counting total cell numbers. Another aliquot was spun in a cytometer at 500 rpm for five minutes and stained with the May-Grunwald-Giemsa stain to identify cell populations. Five hundred cells, excluding epithelial cells, were identified per slide to establish differential cell counts and counts were expressed as percentages and total numbers of dividing cell types. The rest of the BAL fluid was centrifuged at 300 g for 10 minutes at 4°C and the supernatant removed. The BAL fluid pellets were analysed for lymphocyte subsets. The cell subsets were analysed by flow cytometry using CD2, CD3, CD4, CD8, CD20, and HLA-DR monoclonal antibodies7 (Becton Dickinson Co, Mountain View, California, USA). Cell concentrations and surface marker analysis of lymphocytes from BAL fluid are summarised in the figure and table 2. The total cell counts in the BAL fluid from the HCV and control groups were not significantly different (146x8 (27.1) and 147-5 (59 3) x 103/ml, respectively). However, lymphocyte counts and percentages were significantly higher in the HCV group (49-8 (8 4) x 103/ml; 24-4 (96 2)%) than in the controls (7 0 (2 4) x 103/ ml; 5-2 (0 7)%; p<005). Eosinophil counts and percentages were also significantly higher in the HCV group (1-89 (0 84) x 103/ml; (1-2)%) than in the controls (0 03 (0.01) x 103/ ml; 0-1 (0 0)%; p<005). Neutrophil counts were not significantly different in the HCV group (1 1 (0 4) x 103/ml) and controls (1-5 (0-5) x 103/ml). Surface marker analysis oflymphocytes demonstrated significant increases in CD2, CD3, CD4, and HLA-DR. The markers CD20 and CD8 were not increased in the HCV group. The CD4/CD8 ratio was comparable, being 5 09 (1-62) in the HCV group and 3-75 (0 89) in the controls. There was no significant correlation between serum GPT levels and the total or percentages of lymphocytes in the BAL fluid (data not shown). Kubo, Yamaguchi, Fujimoto, Hanaoka, Hayasaka, Honda, Sodeyama, Kiyosawa HLA-DR. We believe that smoking had little effect on the cell populations in the BAL fluid since the number of current smokers was similar in both groups and the cell populations of ex-smokers were almost identical to those who had never smoked. 8 The increased lymphocyte number in patients with chronic hepatitis C was identified as T cells (CD2 + and CD3 +) and the T helper/inducer subset of T cells (CD4 +). The number of lymphocytes expressing HIA-DR, a marker of early T cell activation, was also increased. The numbers of T suppressor/cytotoxic cells (CD8) and B lymphocytes (CD20)
were not increased. The CD4/CD8 ratio showed a tendency to be higher in patients with chronic hepatitis C compared with controls. There have been no previous studies oflympho- cyte 
